Print Icon
 
   

September 2021

Clinical Update: AMP’s CYP2D6 Pharmacogenetic Testing Recommendation  

  

  

An expert-led group from the Association of Molecular Pathology (AMP), with the help of members from the College of American Pathologists, the Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy, released their recommendations for the standardization of CYP2D6 genotyping assays.


The consensus, published in the Journal of Molecular Diagnostics, listed a minimum group of alleles, called Tier 1, that should be included in all genotyping tests, with an additional Tier 2 list containing other notable alleles that are continuing to meet criteria for Tier 1. CYP2D6 has been proven to be responsible for the metabolism of many different and commonly prescribed medications, including beta-blockers, opioids, and antipsychotics.


Genetics Institute of America’s GIAnomics™ Pharmacogenetic Panel follows these latest recommendations by the AMP. We include 17 different allelic variations, which cover all 8 of the Tier 1 recommendations and an additional 9 of the highest rated Tier 2 alleles.


Genetics Institute is committed to exceeding the standards put forth by prestigious organizations, like AMP, and making sure that the panels we offer are the best for your patients’ health and safety.

   
   

Enroll your Practice in GH-101!


Genetics Institute of America is actively recruiting practices to join our study, GH-101! The objective of this study is to take an integrative approach to the fields of pharmacogenomics, cancer genomics, mRNA microarrays and nutrigenomics by identifying DNA and RNA variants in persons with chronic disease. We are looking for Physicians and Physician Groups that currently treat patients with a chronic disease including: cancer, cardiac conditions, diabetes, kidney disease, PTSD. Getting your practice involved is easy and not only gets patients the individualized health information they need but allows your practice to be on the cutting edge of genetic research. Click "Enroll Now" for more information about this study and enrolling your practice.


   

Have You Seen This? 

99% of Veterans Carry Actionable Pharmacogenetic Variants

   

The purpose of pharmacogenetic testing is to inform patients and their physicians about genetic variants that affect drug metabolism. Having this information could affect the type of medication given to a patient or potentially the dosage they are receiving.

It's All in the Genes:

Using Pharmacogenetics to Prevent Adverse Drug Reactions

   

According to the US Food and Drug Administration (FDA), each year, approximately 4.5 million Americans visit their doctors or the emergency room due to Adverse Drug Reactions (ADRs) making it the 4th leading cause of death in the United States.

Changing Corporate Culture:

Feeding the Hungry


Genetics Institute of America believes that it is our responsibility to care for the community we are a part of, and that corporate culture can do more to play a greater role in community solutions.

   
   
   

Thank you for the trust and confidence you have placed in our team here at the Genetics Institute of America. This monthly newsletter is our primary method of communicating to you important information about our testing and assays, general information about the Genetics Institute, as well as information impacting patient care and safety. If you would like to have another person in your practice receive these updates, please forward this to them so that they can subscribe.


   

Ana Perez-Miranda, PhD, MDxT (AAB), MB (ASCP)

Laboratory Manager and Molecular Diagnostics Supervisor

Genetics Institute of America

   

GIA Lab News is an educational service of Genetics Institute of America.


Genetics Institute of America is a national laboratory dedicated to heightening the awareness of early intervention and genetic screening to promote the longevity and quality of life outcomes. Our determination and research allow us to provide next generation DNA sequencing to deliver customized testing for identified genetic related cancers and other diseases.

Follow Us On

4733 W. Atlantic Ave, Suite C16

Delray Beach, FL 33445

Phone: (833) 4GENLAB or (833) 443-6522

HIPAA Fax: (561) 354-5369


You are receiving this email because you opted into receiving communications from Genetics Institute of America online or verbally on the phone, and/or maintain a professional relationship with our laboratory. From time to time, we’ll send newsletters, blog articles, and other educational clinical updates to our subscribers. We hope you find them useful. If not, you can unsubscribe from our list here.


Who do you know that needs to know? Forward this email

Did someone forward this to you? Subscribe

Want to change how you receive these emails?

You can Unsubscribe or Update your preferences


© 2021 Genetics Institute of America. All Rights Reserved.